UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2023
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrant’s name into English)
9 rue André Dumont
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40- F.
Form 20-F ☒ Form 40-F ☐
Celyad Oncology SA
On November 21, 2023, Celyad Oncology SA (the “Company”) published the convening letter to the extraordinary general meeting of shareholders of 22 December 2023.
A copy of the Company’s convening notice is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1 is hereby incorporated by reference into the Company’s Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333-220737).
EXHIBITS
| Exhibit | Description | |
| 99.1 | Convening notice published by the registrant on November 21, 2023 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CELYAD ONCOLOGY SA | ||||||
| Date: November 21, 2023 | By: | /s/ Georges Rawadi | ||||
| Georges Rawadi | ||||||
| Chief Executive Officer | ||||||